Proteostasis Therapeutics Announces Conference Call to Provide Clinical and Scientific Update at 30th Annual North American C...
October 26 2016 - 4:05PM
Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical
company developing small molecule therapeutics to treat diseases
caused by dysfunctional protein processing such as cystic fibrosis,
today announced that the company will hold a conference call on
Thursday, October 27, 2016 at 8:00 a.m. ET to provide an update and
discuss data being presented at the 30th Annual North American
Cystic Fibrosis Conference (NACFC).
This conference call will be held in lieu of the live call and
webcast originally scheduled for Thursday, October 27, 2016 at 8:15
p.m. ET. The company will continue to host a cocktail reception
with analysts and investors onsite at NACFC on Thursday, October
27, 2016 at 8:00 p.m. ET.
The conference call can be accessed by dialing 1-844-534-7315
from the United States or 1-574-990-3007 from outside the United
States and referring to conference ID 4519223. A live webcast and
accompanying slide presentation will be available on the Event
Calendar page in the Investors & Media section of the company’s
website, www.proteostasis.com. A replay of the webcast will be
available on the company’s website shortly after the conclusion of
the conference call.
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a biopharmaceutical company
dedicated to the discovery of groundbreaking therapies to treat
diseases caused by dysfunctional protein processing, such as cystic
fibrosis (CF). Headquartered in Cambridge, MA, the Proteostasis
Therapeutics team focuses on identifying therapies that modulate
the proteostasis imbalance in cells and restore protein function.
Proteostasis Therapeutics is currently enrolling eligible adults
with CF to participate in its Phase 1 clinical trials of PTI-428.
In addition to its multiple programs in cystic fibrosis,
Proteostasis Therapeutics has formed collaborations with Biogen to
research and identify therapeutic candidates for neurodegenerative
disease and with Astellas Pharma, Inc. to research and identify
therapies targeting the Unfolded Protein Response (UPR) pathway.
For more information, visit www.proteostasis.com.
Media Contact:
Katie Engleman, Pure Communications, Inc.
(910) 509-3977
katie@purecommunicationsinc.com
Investor Contact:
Luke Heagle, Pure Communications, Inc.
(910) 726-1372
luke@purecommunicationsinc.com
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Apr 2023 to Apr 2024